BurkleWE. Allopurinol hypersensitivity. Drug Intell Clin Pharm1979; 13: 218–23.
2.
GreenbergMSZambranoSS. Aplastic agranulocytosis after allopurinol therapy. Arth Rheum1972; 15: 413–6.
3.
WilkinsonDG. Allopurinol and agranulocytosis (letter). Lancet1977; 2: 1282–3.
4.
HawsonGATBainBJ. Agranulocytosis with allopurinol. Med J Aust1980; 1: 283.
5.
SwansonMCookR. Drugs, chemicals and blood dyscrasias. Hamilton, IL: Drug Intelligence Inc, 1977.
6.
KramerMGLeventhalJMHutchinsonTAFeinsteinA. An algorithm for the operational assessment of adverse drug reactions: I. Background, description and instruction for use. JAMA1979; 242: 623–32.
7.
HutchinsonTALeventhalJMKramerMSKarchFELipmanAGFeinsteinAR. An algorithm for the operational assessment of adverse drug reactions: II. Demonstration of reproducibility and validity. JAMA1979; 242: 633–8.
8.
VoglerWRBainJAJughleyCMPalmerHGLowreyME. Metabolic and therapeutic effects of allopurinol in patients with leukemia and gout. Am J Med1966; 40: 548–59.
9.
KersleyGD. Treatment of gout by reduction of uric acid production. Ann Rheum Dis1966; 25: 353–5.
10.
KlinebergJRGoldbergSESeegmillerJE. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med1965; 62: 639–47.